bioMérieux, a Durham-based biotech company, paid $90 million recently to acquire a San Diego firm that developed a test for acute kidney injury.
bioMérieux, a Durham-based biotech company, paid $90 million recently to acquire a San Diego firm that developed a test for acute kidney injury. N&O file photo
bioMérieux, a Durham-based biotech company, paid $90 million recently to acquire a San Diego firm that developed a test for acute kidney injury. N&O file photo